FDA clears test to manage potential kidney transplant rejection

Article

The FDA has cleared a test to help manage potential organ rejection in kidney transplant patients.

The FDA has cleared a test to help manage potential organ rejection in kidney transplant patients.

The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus (Zortress), a drug that helps prevent rejection in kidney transplants.

"QMS Everolimus is the first FDA-cleared test physicians can use to maintain appropriate levels of the immunosuppressant everolimus," said Jeffrey Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health.

Thermofisher, the manufacturer of QMS Everolimus, demonstrated the performance of the test by comparing results from the new test with the results from everolimus reference tests used in the clinical trial of everolimus. When the clinical trial blood samples were tested with QMS Everolimus, the results, on average, were similar to those of the clinical trial reference test.

Recent Videos
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Quitting smoking - male hand crushing cigarette | Image Credit: © mbruxelle - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Elisabeth M. Sebesta, MD, answers a question during a Zoom video interview
Katherine Chan, MD, MPH, answers a question during a Zoom virtual interview
Tony Abraham, DO, MPA, a nuclear radiologist
Tony Abraham, DO, MPA, a nuclear radiologist
© 2024 MJH Life Sciences

All rights reserved.